NCT03341793 (MYDIASECRET) is a NA clinical trial of Muscle biopsy and blood test in Diabete Type 2, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

Who is sponsoring NCT03341793?

NCT03341793 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

What drugs are being tested in NCT03341793?

Interventions in NCT03341793: Muscle biopsy and blood test.

What condition does NCT03341793 study?

NCT03341793 studies Diabete Type 2.

Is NCT03341793 still recruiting?

NCT03341793 is currently status unknown. Last updated 15 July 2019.

Last reviewed 2019-07-15 · How we verify

NCT03341793: MYDIASECRET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery

Status unknown NA Last updated 15 July 2019

What this trial tests

NA trial testing Muscle biopsy and blood test in Diabete Type 2 in 40 participants. Status unknown.

Timeline

14 November 2017

Primary endpoint
1 October 2021

1 October 2021

Quick facts

Lead sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	14 November 2017
Primary completion	1 October 2021
Estimated completion	1 October 2021
Sites	1 location across Belgium

Drugs / interventions tested

Muscle biopsy and blood test

Conditions studied

Diabete Type 2 — all drugs for Diabete Type 2 →

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain — full company profile →

Who can join

Adults 18 to 69, any sex, with Diabete Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bariatric surgery is recognized as a therapeutic modality of type 2 diabetes. The mechanisms of this remission of diabetes remain poorly understood. The aim of our research is to characterize the changes in muscle secretome induced by bariatric surgery and to determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by the B cell responsible for the remission of diabetes.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Secretome of Stromal Cancer-Associated Fibroblasts (CAFs): Relevance in Cancer.
Mishra D, Banerjee D. · · 2023 · cited 24× · PMID 36831295 · DOI 10.3390/cells12040628
57<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes.
· 2021 · cited 11× · PMID 34468792 · DOI 10.1007/s00125-021-05519-y
Identification of myokines susceptible to improve glucose homeostasis after bariatric surgery.
Orioli L, Canouil M, Sawadogo K, Ning L, et al · · 2023 · cited 6× · PMID 37638789 · DOI 10.1093/ejendo/lvad122
58<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Stockholm, Sweden, 19 - 23 September 2022.
· 2022 · cited 6× · PMID 35920845 · DOI 10.1007/s00125-022-05755-w

Verify or expand the search:

Other recruiting trials for Diabete Type 2

Currently open trials in the same condition.

NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
NCT07467460 — Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disea · recruiting
NCT07469943 — The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness a · recruiting
NCT07495787 — Magnetic Compression Anastomosis Procedure for Partial Jejunoileal Anastomosis: Assessing the Viability of an Innovative · NA · recruiting
NCT07212075 — Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups · recruiting

Other Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials

Trials by the same sponsor.

NCT07464938 — New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest · NA · recruiting
NCT07173036 — Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification Accordin · NA · not yet recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
NCT07588490 — Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments · NA · recruiting
NCT07161219 — Implementation of New Exercise Protocols in Cardiac Rehabilitation. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03341793 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Last refreshed: 15 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03341793.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing